Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stent and application thereof

A matrix and drug technology, applied in the field of medical devices, can solve the problems of narrow urinary system pipeline, increased economic burden, damage repair or therapeutic effect, and achieve high treatment efficiency, less drug dosage and uniform release effect

Pending Publication Date: 2020-09-29
上海浦瑞通医疗科技有限公司
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the stents on the market are only for physical support and drainage, and do not repair or treat the injury. After the stent is implanted, it may stimulate the body to cause inflammation, causing scar tissue to form at the damaged site, resulting in restenosis of the urinary system.
For restenosis of the urinary tract, repeated operations may easily cause other complications, which not only bring great physical and mental pain to the patient, but also increase the economic burden

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stent and application thereof
  • Stent and application thereof
  • Stent and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] This embodiment provides a stent, including a stent matrix and a glucocorticoid-containing drug dispersed in the stent matrix, wherein the glucocorticoid-containing drug is mometasone furoate, the average particle size is 5000 mesh, and the material of the stent matrix is Silicone rubber, the crosslink density of silicone rubber is 5000g / mol.

[0097] This embodiment provides a preparation method for a stent, comprising: 10 parts by weight of a drug (mometasone furoate) and 30 parts by weight of silicone rubber (HTV medical silicone rubber, molecular weight 20-1 million), 1.2 parts by weight of a cross-linking agent ( Hydroxyl silicone oil), 1.2 parts by weight of catalyst (platinum), kneaded on a rubber mixer until uniform, vulcanized and crosslinked, and extruded into a support on an extruder.

[0098] According to the test method of the standard GB / T531, the physical properties of the stent of this embodiment were tested, and it can be known that the hardness of the ...

Embodiment 2

[0147] This embodiment provides a stent, including a stent matrix and a drug containing a glucocorticoid dispersed in the stent matrix, wherein the material of the stent matrix is ​​caprolactone-lactide copolymer, and the drug containing a glucocorticoid is budesel Germany.

[0148] This embodiment provides a method for preparing a stent, comprising: dissolving 20 parts by weight of a degradable material (caprolactone-lactide copolymer), 1.5 parts by weight of a drug (budesonide) containing a glucocorticoid in 50 ml of acetone , then add 2 parts by weight of water-soluble polymer (cellulose, cellulose is first dissolved in 5ml of water, and then added to the acetone solution) for mixing, the solvent is removed, heated and shaped to obtain a scaffold.

[0149] The support force of the stent was tested using a radial support dynamometer, and the force value of 10% compression was 92N.

[0150] Calculate the content of drug ingredients in the sample according to the weight, use ...

Embodiment 3

[0152] This embodiment provides a stent, including a stent matrix and a drug containing a glucocorticoid dispersed in the stent matrix, wherein the material of the stent matrix is ​​polyglycolic acid, and the drug containing a glucocorticoid is mometasone furoate.

[0153] This embodiment provides a preparation method for a stent, comprising: 80 parts by weight of a degradable material (polyglycolic acid), 5 parts by weight of a drug containing a glucocorticoid (mometasone furoate) and 10 parts by weight of a water-soluble polymer ( Chitosan) was uniformly mixed under melting conditions (140° C.), extruded and shaped to obtain a scaffold.

[0154] The support force of the stent was tested using a radial support dynamometer, and the force value for 10% compression was 103N.

[0155] Calculate the content of drug ingredients in the sample according to the weight, use a drug dissolution tester to conduct drug dissolution and degradation experiments on the sample in a simulated ur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Crosslink densityaaaaaaaaaa
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention provides a stent and application thereof. The stent is used for a urinary system tract; the stent comprises a stent matrix and drug arranged on the stent matrix; when the stent is implanted into the urinary system tract, the stent matrix achieves the support and draining effects on the urinary system tract; the drug is used for preventing or reducing the occurrence of urinary systemtract restenosis; and the stent has the treatment effects of low dosage and high efficiency, and has the longer drug release period and better slow release capability. In addition, the stent providedby the invention can achieve the targeting effect; the condition that during oral administration, the drug needs to be metabolized firstly by the livers is effectively avoided; the use dosage is about10 percent of that of an oral administration or injection mode; and the side effect of the drug on the whole body is greatly reduced.

Description

technical field [0001] The invention belongs to the field of medical instruments, and relates to a bracket and its application. Background technique [0002] Urinary tract stenosis (such as ureteral stricture and urethral stricture) is a common disease of the urinary system. In addition to congenital stenosis, inflammation and injury are the main causes of urinary tract stenosis. For example, common causes include ureteroscopy, holmium and thulium laser Lithotripsy, various pelvic surgeries, ureter infection, urethral lumen infection, etc. [0003] At present, clinical treatment methods for urinary tract stenosis include repeated dilatation, incision, anastomosis, dragging, and replacement plastic surgery. After surgery, patients need to implant stents for support and drainage. At present, the stents on the market are only for physical support and drainage, and do not repair or treat the injury. After the stent is implanted, it may stimulate the body to cause inflammation, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F2/82A61M27/00A61L31/08A61L31/16
CPCA61F2/82A61M27/008A61L31/16A61L31/08A61F2250/0067A61F2240/002A61F2240/008A61L2300/602A61L2300/43A61L2300/404
Inventor 夏佩佩晏伟魏征
Owner 上海浦瑞通医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com